F

Frontier Biotechnologies Inc
SSE:688221

Watchlist Manager
Frontier Biotechnologies Inc
SSE:688221
Watchlist
Price: 28.15 CNY 19.99% Market Closed
Market Cap: 10.5B CNY

Intrinsic Value

The intrinsic value of one Frontier Biotechnologies Inc stock under the Base Case scenario is 4.23 CNY. Compared to the current market price of 28.15 CNY, Frontier Biotechnologies Inc is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
4.23 CNY
Overvaluation 85%
Intrinsic Value
Price
F
Worst Case
Base Case
Best Case

Valuation History
Frontier Biotechnologies Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about Frontier Biotechnologies Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Frontier Biotechnologies Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Frontier Biotechnologies Inc.

Explain Valuation
Compare Frontier Biotechnologies Inc to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about Frontier Biotechnologies Inc?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Frontier Biotechnologies Inc

Current Assets 1.1B
Receivables 269m
Other Current Assets 861m
Non-Current Assets 594m
Long-Term Investments 28m
PP&E 393m
Intangibles 144m
Other Non-Current Assets 29m
Current Liabilities 415m
Accounts Payable 17m
Accrued Liabilities 13m
Short-Term Debt 241m
Other Current Liabilities 144m
Non-Current Liabilities 212m
Long-Term Debt 144m
Other Non-Current Liabilities 68m
Efficiency

Free Cash Flow Analysis
Frontier Biotechnologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Frontier Biotechnologies Inc

Revenue
133.2m CNY
Cost of Revenue
-92.1m CNY
Gross Profit
41.1m CNY
Operating Expenses
-303.8m CNY
Operating Income
-262.7m CNY
Other Expenses
72.9m CNY
Net Income
-189.8m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

Frontier Biotechnologies Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score

Frontier Biotechnologies Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Frontier Biotechnologies Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
59/100
Solvency
Score

Frontier Biotechnologies Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Frontier Biotechnologies Inc

There are no price targets for Frontier Biotechnologies Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Frontier Biotechnologies Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for Frontier Biotechnologies Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one Frontier Biotechnologies Inc stock?

The intrinsic value of one Frontier Biotechnologies Inc stock under the Base Case scenario is 4.23 CNY.

Is Frontier Biotechnologies Inc stock undervalued or overvalued?

Compared to the current market price of 28.15 CNY, Frontier Biotechnologies Inc is Overvalued by 85%.

Back to Top